From: Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
Subgroup | Study arm | Clinical success | Microbiologic eradication | Resistance at baseline | Emergent resistance | ||||
---|---|---|---|---|---|---|---|---|---|
 |  | PA isolates (n) | % (range) | PA isolates (n) | % (range) | PA isolates (n) | % (range) | PA isolates (n) | % (range) |
Blinding present | I | 15 | 21.1 (0.0-42.1) | 61 | 47.8 (25.0-70.6) | NR | Â | 67 | 56.9 (42.9-77.8) |
 | C | 20 | 78.7 (75.0-82.4) | 65 | 52.1 (27.7-76.5) | NR |  | 75 | 25.3 (6.3-41.7) |
 |  |  |  |  |  |  | |||
Comparator drug class | Â | Â | Â | Â | Â | Â | Â | Â | Â |
β-lactam | I | 108 | 39.9 (0.0-72.0) | 95 | 52.7 (0.0-70.6) | 81 | 14.6 (4.2-24.0) | 137 | 31.3 (5.6-52.6) |
 | C | 107 | 84.7 (0.0-100.0) | 110 | 56.3 (0.0-100.0) | 76 | 2.5 (0.0-7.4) | 131 | 20.1 (4.8-56.5) |
 |  |  |  |  |  | ||||
Fluoro-quinolone | I | 47 | 59.7 (41.2-72.0) | 95 | 26.5 (25.0-29.4) | NR | Â | 83 | 41.6 (5.6-77.8) |
 | C | 47 | 73.6 (64.7-85.0) | 110 | 45.5 (27.7-58.8) | NR |  | 89 | 20.7 (6.3-41.7) |
 |  |  |  |  |  |  | |||
Nosocomial pneumonia | I | 72 | 55.5 (41.2-72.0) | 71 | 40.2 (25.0-50.0) | 57 | 19.9 (4.2-24.0) | 87 | 29.8 (5.6-52.6) |
 | C | 75 | 75.2 (64.7-85.0) | 77 | 62.6 (50.0-76.5) | 55 | 3.7 (0.0-7.4) | 85 | 15.0 (6.3-35.7) |
 |  |  |  |  |  | ||||
VAP subgroup | I | Â | 60.3 (41.2-72.0) | Â | 30.4 (25.0-35.7) | 25 | 24.0 (NA) | 55 | 30.4 (5.6-52.6) |
 | C |  | 78.7 (71.0-85.0) |  | 57.5 (50.0-65.0) | 28 | 0.0 (NA) | 58 | 16.3 (6.3-35.7) |
 |  |  |  | [39] |  |  | |||
North America only | I | 36 | 37.7 (0.0-72.0) | 78 | 41.7 (25.0-70.6) | NR | Â | 71 | 44.4 (5.6-77.8) |
 | C | 37 | 74.9 (64.0-85.0) | 82 | 54.3 (27.7-76.5) | NR |  | 75 | 25.3 (6.3-41.7) |
 |  |  |  |  |  |  |